The decline in revenue can be attributed to decreased sales of the Vitoss Synthetic Bone Graft Substitute products, which declined 6 percent in 4Q 2010 compared to 4Q 2009. Although sales of Vitoss Bioactive Foam products and Vitoss Morsels increased 3 percent and 1 percent, respectively, these increases were offset by a significant decrease in sales of Vitoss Foam products.
Read the company news release about Orthovita’s 4Q financial results (pdf).
Read other coverage about device companies’ financial results:
– MAKO Surgical Posts 4Q Revenue of $14.8M, 67% Increase
